Heart Attack

Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024

Zembrace® SymTouch® and Tosymra® will be marketed by Tonix Medicines, Tonix’s wholly-owned commercial subsidiary Commercial capabilities prepare Tonix for the…

3 days ago

What Are The Symptoms to Watch For Of A Heart Attack For Men And For Woman

A heart attack, medically known as myocardial infarction, occurs when the blood supply to the heart is blocked, often by…

1 week ago

Cardio Diagnostics Holdings, Inc. to Showcase HeartRisk and Actionable Clinical Intelligence Version 3 at the American College of Cardiology’s 73rd Annual Scientific Session

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announces that the Company will showcase its…

1 week ago

ProQR Announces Year End 2023 Operating and Financial Results

Preclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GALT1…

1 week ago

SS Innovations’ SSi Mantra Surgical Robotic System used to perform Mitral Valve Replacement

The first Mitral Valve Replacement using the Made in India SSi Mantra Surgical Robotic System was successfully performed at the…

1 week ago

HeartBeam Receives Two New US Patents for its Core Cardiac Monitoring Technology

Company Continues Expanding its Intellectual Property Footprint, Now has 14 US and 4 International PatentsSANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ:…

2 weeks ago

Cardio Diagnostics Holdings, Inc. Announces Issuance of Second U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease

Company Continues to Build and Expand the Global IP Portfolio of Its One-of-a-Kind TechnologyCHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO),…

2 weeks ago

BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

CardiAMP cell therapy-treated patients had 37% relative risk reduction in heart death equivalent (death, heart transplant, left ventricular assist device…

3 weeks ago

Kidney Foundation Marks 60th Anniversary

Learn more during Kidney Health Month in MarchMontreal, Quebec--(Newsfile Corp. - February 29, 2024) - When the Kidney Foundation of…

3 weeks ago

Biotricity Receives Health Canada Clearance for Biotres

Well Positioned to Enter US $1.56 Billion Canadian Cardiology Devices MarketREDWOOD CITY, CA / ACCESSWIRE / February 29, 2024 /…

3 weeks ago